Growth factor treatment of demyelinating disease

At last, a leap into the light

Richard M. Ransohoff, Charles L Howe, Moses Rodriguez

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Researchers seeking treatments for multiple sclerosis (MS) have long dreamed of using neurotrophic factors to enhance remyelination. Previous attempts to apply trophic support for oligodendrocytes in experimental demyelination uniformly produced complicated outcomes that reflected unexpected effects on immune or inflammatory responses and could be interpreted only with caution. Now, two recent publications have demonstrated convincingly that cytokines of the interleukin (IL)-6 superfamily can ameliorate experimental autoimmune encephalomyelitis and promote oligodendrocyte survival, without demonstrable effect on inflammation or immune responses.

Original languageEnglish (US)
Pages (from-to)512-516
Number of pages5
JournalTrends in Immunology
Volume23
Issue number11
DOIs
StatePublished - Nov 1 2002

Fingerprint

Oligodendroglia
Demyelinating Diseases
Intercellular Signaling Peptides and Proteins
Light
Autoimmune Experimental Encephalomyelitis
Nerve Growth Factors
Multiple Sclerosis
Interleukin-6
Research Personnel
Cytokines
Inflammation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Growth factor treatment of demyelinating disease : At last, a leap into the light. / Ransohoff, Richard M.; Howe, Charles L; Rodriguez, Moses.

In: Trends in Immunology, Vol. 23, No. 11, 01.11.2002, p. 512-516.

Research output: Contribution to journalArticle

Ransohoff, Richard M. ; Howe, Charles L ; Rodriguez, Moses. / Growth factor treatment of demyelinating disease : At last, a leap into the light. In: Trends in Immunology. 2002 ; Vol. 23, No. 11. pp. 512-516.
@article{9aa1ed0041574e2187fae26ca6454aaf,
title = "Growth factor treatment of demyelinating disease: At last, a leap into the light",
abstract = "Researchers seeking treatments for multiple sclerosis (MS) have long dreamed of using neurotrophic factors to enhance remyelination. Previous attempts to apply trophic support for oligodendrocytes in experimental demyelination uniformly produced complicated outcomes that reflected unexpected effects on immune or inflammatory responses and could be interpreted only with caution. Now, two recent publications have demonstrated convincingly that cytokines of the interleukin (IL)-6 superfamily can ameliorate experimental autoimmune encephalomyelitis and promote oligodendrocyte survival, without demonstrable effect on inflammation or immune responses.",
author = "Ransohoff, {Richard M.} and Howe, {Charles L} and Moses Rodriguez",
year = "2002",
month = "11",
day = "1",
doi = "10.1016/S1471-4906(02)02321-9",
language = "English (US)",
volume = "23",
pages = "512--516",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Growth factor treatment of demyelinating disease

T2 - At last, a leap into the light

AU - Ransohoff, Richard M.

AU - Howe, Charles L

AU - Rodriguez, Moses

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Researchers seeking treatments for multiple sclerosis (MS) have long dreamed of using neurotrophic factors to enhance remyelination. Previous attempts to apply trophic support for oligodendrocytes in experimental demyelination uniformly produced complicated outcomes that reflected unexpected effects on immune or inflammatory responses and could be interpreted only with caution. Now, two recent publications have demonstrated convincingly that cytokines of the interleukin (IL)-6 superfamily can ameliorate experimental autoimmune encephalomyelitis and promote oligodendrocyte survival, without demonstrable effect on inflammation or immune responses.

AB - Researchers seeking treatments for multiple sclerosis (MS) have long dreamed of using neurotrophic factors to enhance remyelination. Previous attempts to apply trophic support for oligodendrocytes in experimental demyelination uniformly produced complicated outcomes that reflected unexpected effects on immune or inflammatory responses and could be interpreted only with caution. Now, two recent publications have demonstrated convincingly that cytokines of the interleukin (IL)-6 superfamily can ameliorate experimental autoimmune encephalomyelitis and promote oligodendrocyte survival, without demonstrable effect on inflammation or immune responses.

UR - http://www.scopus.com/inward/record.url?scp=0036838576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036838576&partnerID=8YFLogxK

U2 - 10.1016/S1471-4906(02)02321-9

DO - 10.1016/S1471-4906(02)02321-9

M3 - Article

VL - 23

SP - 512

EP - 516

JO - Trends in Immunology

JF - Trends in Immunology

SN - 1471-4906

IS - 11

ER -